We first demonstrated that injection of AAV-MOR increased MOR immunoreactivity in brain. Using cell culture, we found that AAV-MOR transfection can increase MOR binding and MOR immunoreactivity in 293 cells. These data suggest that treatment with AAV-MOR enhances MOR expression in vivo and in vitro. AAV-MOR or AAV-GFP was then injected into the nucleus Accumbens (NAc) or ventral tegmental area (VTA) of adult C57/BL6 mice. Two weeks after viral infection, animals received methamphetamine or saline for 5 consecutive days. Repeated administration of methamphetamine progressively increased locomotor activity;this sensitization reaction was attenuated by NAc AAV-MOR pretreatment. In contrast, administration of AAV-MOR to VTA enhanced methamphetamine sensitization. AAV-MOR significantly enhanced DA levels in VTA after VTA infection but reduced DOPAC/DA turnover in the NAc after NAc injection. Our data suggest a differential modulation of methamphetamine sensitization by overexpression of MOR in NAc and VTA.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Institute on Drug Abuse
Zip Code
Reiner, David J; Yu, Seong-Jin; Shen, Hui et al. (2014) 9-Cis retinoic acid protects against methamphetamine-induced neurotoxicity in nigrostriatal dopamine neurons. Neurotox Res 25:248-61
Luo, Yu; Shen, Hui; Liu, Hua-Shan et al. (2013) CART peptide induces neuroregeneration in stroke rats. J Cereb Blood Flow Metab 33:300-10
Henderson, Mark J; Richie, Christopher T; Airavaara, Mikko et al. (2013) Mesencephalic astrocyte-derived neurotrophic factor (MANF) secretion and cell surface binding are modulated by KDEL receptors. J Biol Chem 288:4209-25